Specific to blood tumors, one report showed the regulation of FTO-dependent m6A demethylation on the targeted drug resistance of TKIs [16], but no evidence about the association between blood tumors’ METTL3 expression and BM-related chemoresistance has been reported. Here, METTL3 is linked to hematopoietic and lymphoid system neoplasm.